首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Effect of the traditional chinese medicines Chan Su Lu‐Shen‐Wan Dan Shen and Asian Ginseng on Serum Digoxin measurement by Tina‐quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays
【2h】

Effect of the traditional chinese medicines Chan Su Lu‐Shen‐Wan Dan Shen and Asian Ginseng on Serum Digoxin measurement by Tina‐quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays

机译:中药陈苏鹿神丸丹参和亚洲人参对蒂娜定量(Roche)和Synchron LX系统(贝克曼)地高辛免疫测定法测定血清地高辛的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chan Su, Lu‐Shen‐Wan, Dan Shen, and Asian ginseng are traditionally used to treat a number of conditions, including cardiovascular disease. All of these traditional Chinese medicines exhibit cardioactive properties. Digoxin is a cardioactive drug with a narrow therapeutic range (0.8–1.9 ng/mL). A patient taking digoxin may also take these Chinese medicines for their cardiotonic effects. Moreover, the active components of these medicines that are responsible for cardiotonic effects bear structural similarities to digoxin. Therefore, we studied the potential interference of these Chinese medicines with two digoxin immunoassays—the Tina‐quant (Roche Diagnostics) and the Beckman (Synchron LX system)—and compared the values with the fluorescence polarization immunoassay (FPIA; Abbott Laboratories). When very small amounts (2–5 μL) of aqueous extract of Chan Su or Lu‐Shen‐Wan were added to drug‐free serum, we observed high digoxin‐like immunoreactivity with the FPIA. In contrast, when ethyl acetate extract of Dan Shen or microliter amounts of ginseng extract were added todrug‐free serum, we observed modest digoxin‐like immunoreactivity with the FPIA, but no apparent digoxin activity with the Roche and Beckman digoxin immunoassays. When aliquots of a digoxin pool prepared from patients receiving digoxin were supplemented with these Chinese medicines, we observed the most significant interference with the FPIA. The presence of endogenous digoxin‐like immunoreactive substances can have additive effects with these Chinese medicines and falsely increase apparent digoxin levels by the FPIA. On the other hand, the Roche and Beckman assays were free from interference from DLIS but showed significant interference from Chan Su and Lu‐Shen‐Wan. We conclude that the FPIA showed the most significant interference from all four of the Chinese medicines we studied. However, the Roche and Beckman assays showed no interference from two (Dan Shen and Asian ginseng) of the four Chinese medicines we studied. J. Clin. Lab. Anal. 17:22–27, 2003. © 2003 Wiley‐Liss, Inc.
机译:传统上使用Chan Su,Lu-Shen-Wan,Dan Shen和西洋参来治疗多种疾病,包括心血管疾病。所有这些中药均表现出心脏活性。地高辛是一种心脏活性药物,治疗范围狭窄(0.8-1.9 ng / mL)。服用地高辛的患者也可以服用这些中药,因为它们具有强心作用。此外,这些药物的引起强心作用的活性成分与地高辛具有相似的结构。因此,我们用两种地高辛免疫测定法(Tina-quant(罗氏诊断公司)和贝克曼(Synchron LX系统))研究了这些中药的潜在干扰,并将其与荧光偏振免疫测定法(FPIA; Abbott实验室)进行了比较。当将少量(2–5μL)的Chan Su或Lu-Shen-Wan水提取物添加到无药血清中时,我们发现与FPIA的地高辛样免疫反应性很高。相反,当将丹参乙酸乙酯提取物或微升人参提取物添加到无药血清中时,我们观察到与FPIA的地高辛样免疫反应性适中,但在罗氏和贝克曼地高辛免疫分析法中却没有明显的地高辛活性。当从接受地高辛的患者准备的地高辛库的等分试样中补充这些中药时,我们观察到对FPIA的干扰最大。内源性地高辛样免疫反应性物质的存在可对这些中药产生累加效应,并通过FPIA错误地增加表观地高辛水平。另一方面,Roche和Beckman测定不受DLIS的干扰,但显示出Chan Su和Lu-Shen-Wan的明显干扰。我们得出的结论是,FPIA对我们研究的所有四种中药都表现出最大的干扰。但是,Roche和Beckman分析显示我们研究的四种中药中的两种(丹参和亚洲人参)没有干扰。 J.临床实验室肛门17:22–27,2003。©2003 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号